-
1.发明公开
公开(公告)号：EP1680505A1
公开(公告)日：2006-07-19
申请号：EP04798999.1
申请日：2004-11-05
发明人： DESIRE, Laurent
CPC分类号： C12N9/6421 , A61K38/00
摘要： The present invention relates generally to the fields of genetics, biochemistry, medicinal chemistry and medicine. The present invention more particularly discloses the identification of a human gene variant involved in neuropathological conditions, and methods for the diagnosis, prevention and treatment of such diseases and related disorders, as well as for the screening of therapeutically active drugs. The present invention relates to catalytically active beta-secretase (Memapsin2, BACE) variants, and nucleic acids encoding them. The invention is useful in the identification of agents that inhibit the activity of a particular BACE isoform and thus agents and therapies affecting the genesis, development or progression of neuropathological conditions, including Alzheimer's disease and dementia.
-
公开(公告)号：EP1566453A2
公开(公告)日：2005-08-24
申请号：EP05003839.7
申请日：1999-03-11
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6809 , C12Q1/6827 , C12Q1/6837 , C12Q2539/105 , C12Q2537/113 , C12Q2521/301 , C12Q2565/501
摘要： L'invention concerne un procédé d'identification et/ou de clonage de régions d'acides nucléiques représentatives de différences qualitatives associées à des événements d'épissages alternatifs et/ou à des insertions, délétions se trouvant dans des régions du génome transcrites en ARN, entre deux situations physiologiques, comprenant soit l'hybridation d'ARN provenant de la situation test avec les ADNc provenant de la situation de référence et/ou réciproquement, soit l'hybridation d'ADNc double-brin provenant de la situation test avec les ADNc provenant de la situation de référence et ; l'identification et/ou le clonage d'acides nucléiques représentatifs des différences qualitatives. L'invention concerne également des compositions ou banques d'acides nucléiques représentatifs de différences qualitatives entre deux situations physiologiques, susceptibles d'être obtenues par le procédé décrit ci-dessus, ainsi que leur utilisation comme sonde, pour l'identification de gènes ou molécules d'intérêt, ou encore par exemple dans des méthodes de pharmacogénomique, et de profilage de molécules vis à vis de leurs effets thérapeutiques et/ou toxiques. L'invention concerne aussi l'utilisation des dysrégulations de l'épissage des ARN comme marqueurs de prédiction de la toxicité et/ou de l'efficacité de molécules, ainsi que comme marqueurs de pharmacogénomique.
摘要翻译： 用于鉴定和/或克隆在两种不同生理情况下不同剪接的核酸区域的方法包括将源自测试情况的RNA与源自参考情况的cDNA杂交，并鉴定和/或克隆对应于差异剪接的核酸。 还包括以下独立权利要求：（1）用于鉴定和/或克隆在两种不同生理情况A和B中不同剪接的核酸区域的方法，包括：（a）在mRNA之间的液相中形成异源双链体 源自情境A和源自情境B的cDNA; （b）在来自情况B的mRNA和源自病例A的cDNA之间的液相中形成异源双链体; 和（c）鉴定和/或克隆在步骤（a）和（b）中未配对的RNA区域; （2）用于鉴定和/或克隆在两种不同生理情况A和B中不同剪接的核酸区域的方法，包括：（a）在源自情况A的mRNA和来自情况B的cDNA之间形成异源双链体，其中 mRNA或cDNA被固定在载体上; （b）在情况B的mRNA和源自情况A的mRNA之间形成异源双链体，其中mRNA或cDNA被固定在载体上; 和（c）鉴定和/或克隆在步骤（a）和（b）中未配对的RNA区域; （3）包含通过上述方法鉴定和/或克隆的核酸的组合物; （4）核酸组合物，其包含对应于区别细胞或组织的两种生理状况的可选剪接的核酸; （5）鉴别细胞或组织的两种生理状况或用这种核酸转化的微生物的特异于选择性剪接的核酸或寡核苷酸文库; （6）包含能够干扰通过上述方法鉴定的可变剪接产物的化合物的组合物。 活动：无给定。 行动机制：无给予。
-
3.发明公开Tricyclic hydroxamate and benzaminde derivatives, compositions and methods 审中-公开Tricyclische Hydroxamat-和Benzamid-Derivate，Zusammensetzungen und Methoden
公开(公告)号：EP1541549A1
公开(公告)日：2005-06-15
申请号：EP03293143.8
申请日：2003-12-12
IPC分类号： C07C259/10 , C07C233/80 , C07C259/06 , A61K31/167 , A61P35/00
CPC分类号： C07C259/10 , C07C233/80 , C07C259/06 , C07C2602/10
摘要： The present invention relates to compounds and methods for inhibiting histone deacetylase enzymatic activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo , to inhibit histone deacetylases (HDACs), and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, and also central nervous system diseases. It further deals with processes for preparing said compounds.
摘要翻译： 本发明涉及抑制组蛋白脱乙酰酶酶活性的化合物和方法。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制组蛋白脱乙酰酶（HDAC），以及在治疗HDAC介导的病症，癌症，增殖性病症 ，牛皮癣以及中枢神经系统疾病。 它还涉及制备所述化合物的方法。
-
4.发明公开VARIANTS DE KALLIKREIN-2 ET KALLIKREINE-3 HUMAINES ET LEURS UTILISATIONS 审中-公开激肽释放酶HUMAN-2的变型和激肽释放酶3及其用途
公开(公告)号：EP1483381A2
公开(公告)日：2004-12-08
申请号：EP03743925.4
申请日：2003-03-14
IPC分类号： C12N9/64
CPC分类号： C12N9/6445
摘要： The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods of detecting, characterising and/or treating cancer pathologies, such as prostate cancer. The invention also relates to methods of identifying and screening compounds that are active in said pathologies. Furthermore, the invention relates to compounds, genes, cells, plasmids or compositions that are used to carry out the above-mentioned methods. More specifically, the invention outlines the role of variants of human kallikrein-2 and human kallikrein-3, also known as PSA, in the aforementioned pathologies and the uses of same as therapeutic, diagnostic or experimental targets.
-
公开(公告)号：EP1220950A2
公开(公告)日：2002-07-10
申请号：EP00962602.9
申请日：2000-09-12
CPC分类号： C12Q1/6809 , C12N15/1034 , C12Q1/6837
摘要： The invention concerns novel methods for determining the toxic potential of test compounds, as well as equipment and kits for implementing said methods. The invention also concerns methods for generating nucleic acid sequences for use as genetic markers of toxicity. The invention is based in particular on the constitution of differential libraries of nucleic acids, characteristic of situations wherein the viability and/or cell proliferation are disrupted, and for demonstrating that said libraries are useful for very dependably assessing with high degree of sensitivity the toxic profile of compounds. The invention is particularly useful in the pharmaceutical industry, for analysing the toxic profile of molecules to be used for pharmaceutical preparation and/or in pharmaceutical compositions.
-
公开(公告)号：EP2260113A2
公开(公告)日：2010-12-15
申请号：EP09754074.4
申请日：2009-03-30
发明人： JARRIGE-LE PRADO, Anne-Charlotte , BEURDELEY, Pascale , PALLARES, Diego , ROUET, Fabien , BRACCO, Laurent
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/6837 , C12Q2600/106 , C12Q2600/158 , C12Q2539/105
摘要： The present application relates to the methods and compositions useful for diagnosing Alzheimer’s disease in mammals, particularly humans. The application particularly describes serous markers for Alzheimer’s disease and the uses thereof in methods of diagnosis. The application also relates to the tools and/or kits useful for implementing these methods (reagents, probes, primers, antibodies, chips, cells, etc.) and the preparation and uses thereof. The invention is useful for detecting the presence or development of Alzheimer’s disease in mammals, including during the early phase, and for predicting the effectiveness of Alzheimer’s disease treatment.
-
7.发明授权
公开(公告)号：EP1594498B1
公开(公告)日：2009-07-22
申请号：EP04712083.7
申请日：2004-02-18
IPC分类号： A61K31/437 , A61K31/444 , A61K31/706 , A61P27/06 , A61P27/02
CPC分类号： A61K31/437 , A61K31/444 , A61K31/706
摘要： The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods for the detection, characterisation and/or treatment (or management) of neurodegenerative pathologies. The invention also relates to methods for the identification or screening of compounds active in the aforementioned pathologies. The invention further relates to the compounds, genes, cells, plasmids or compositions which are used to carry out the above-mentioned methods. The invention is based on the identification of the role of phosphodiesterase 4B, the peripheral benzodiazepine receptor (PBR) and GABA(A)-type GABA receptors in neurodegenerative pathologies. In addition, the invention outlines the use of same as therapeutic, diagnostic or experimental markers or targets for said disorders.
-
公开(公告)号：EP1062364B1
公开(公告)日：2005-05-11
申请号：EP99909002.0
申请日：1999-03-11
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6809 , C12Q1/6827 , C12Q1/6837 , C12Q2539/105 , C12Q2537/113 , C12Q2521/301 , C12Q2565/501
摘要： The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridisation of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridisation of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.
-
公开(公告)号：EP1480966A1
公开(公告)日：2004-12-01
申请号：EP03743474.3
申请日：2003-02-28
发明人： LEBLANC, Véronique , LEBLOND, Bertrand , MELLE-MILOVANOVIC, Dominique , LOPEZ RODRIGUEZ, Maria, Luz , VISO BERONDA, Alma , BEAUSOLEIL, Eric , PICARD, Virginie , PINAR PINEDO, Maria del Carmen , TAVERNE, Thierry
IPC分类号： C07D309/38 , C07D405/12 , C07D405/14 , C07D407/12 , C07D411/14 , C07D407/14 , A61K31/351
CPC分类号： A61K31/351 , C07D309/40
摘要： The present invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having anti-proliferative activities, as well as methods for treating various diseases associated with abnormal cell proliferation, including cancer, by administering said compounds. It further deals with pharmaceutical compositions comprising said compounds, more particularly useful to treat cancers.
-
10.发明公开Méthodes et compositions pour la détection d'évènements pathologiques 有权Verfahren und Zusammensetzungenfürdie Detektion pathologischer Ereignisse
公开(公告)号：EP1382693A1
公开(公告)日：2004-01-21
申请号：EP03017827.1
申请日：2000-09-05
IPC分类号： C12Q1/68
CPC分类号： G01N33/56972 , C12Q1/6809
摘要： La présente invention concerne de nouvelles compositions et méthodes pour la détection d'événements pathologiques. Elle concerne plus particulièrement des méthodes pour la détection in vitro de la présence d'une pathologie ou d'un événement pathologique chez un sujet, comprenant le prélèvement d'un échantillon de cellules sanguines du sujet et la détermination de la présence, dans cet échantillon, de cellules sanguines présentant un état physiologique caractéristique de la pathologie. L'invention concerne également des outils, kits et compositions pour la mise en oeuvre de telles méthodes, ainsi que leurs utilisations dans le domaine de la santé humaine ou animale, ou en recherche expérimentale par exemple.
摘要翻译： 疾病的体外检测包括在血液样品中测定作为疾病特征的血细胞的生理状态是新的。 还包括以下独立权利要求：（1）制备疾病特征性的核酸文库; （2）制备疾病发展中特定阶段特征的核酸文库; （3）含有对来自患病生物体的血细胞中表达水平被修饰的基因特异性的核酸的制剂; （4）含有来自患病生物的血细胞特征的基因的含有剪接形式的核酸的制备物; 和（5）用于确定疾病的试剂盒，其含有特异性核酸的文库，所述核酸文库对于患病生物体的血细胞的基因表达特征的改变。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.032 秒)
